CGM Glucose Dynamics Modeling Patent Landscape 2026
The University of Virginia Patent Foundation holds a commanding position in CGM glucose dynamics modeling, accounting for the largest share of patent records among the top hundred filers by a wide margin. The field is still expanding on a multi-year basis, though annual volume has eased from its 2023 peak and the most recent filing years remain further understated by publication lag.
University of Virginia leads a highly concentrated field with commercial challengers emerging
The University of Virginia. Patent Foundation ranks first with 78 patent records, followed by Medtronic MiniMed Inc at 33 and WellDoc Inc at 9, making the top three filers responsible for the overwhelming majority of documented activity.
The top five filers — University of Virginia. Patent Foundation, Medtronic MiniMed, WellDoc, Dexcom, and Marc D. Breton — collectively account for 88% of the hundred largest filers’ combined total, signaling an unusually tight concentration for a field that is still in its growth phase.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | University of Virginia Patent Foundation | 78 | |
| 2 | Medtronic MiniMed Inc | 33 | |
| 3 | WellDoc Inc | 9 | |
| 4 | Dexcom Inc | 8 | |
| 5 | BRETON MARC D | 2 | |
| 6 | Abbott Diabetes Care Inc | 2 | |
| 7 | DR K MOHAMED RAFI | 1 | |
| 8 | GHORPADE HEM ARUN | 1 | |
| 9 | Zhongshan Hospital Fudan University | 1 | |
| 10 | Zeus Company Inc | 1 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | SAHOO DIPTI MAYEE | 1 | |
| 12 | DR N T PRAMATHESH MISHRA | 1 | |
| 13 | PATEK STEPHEN D | 1 | |
| 14 | DR N VENKATARAMANAIAH | 1 | |
| 15 | DR HARISHCHANDER ANANDARAM | 1 | |
| 16 | DR M HEMALATHA | 1 | |
| 17 | DR SAJITH S | 1 | |
| 18 | University of Padova | 1 | |
| 19 | KANDI SAMIKSHA SHRIDHAR | 1 | |
| 20 | DR LUCY MOHAPATRA | 1 |
The leader’s position reflects a sustained academic-origin R&D program that has spun out both foundational algorithms and clinical-decision-support architectures; challengers such as Medtronic MiniMed and Dexcom represent the commercial translation layer, suggesting that the gap between foundational research and device-level implementation remains the primary competitive axis.
The most recent 18–24 months of filings are under-represented due to standard patent publication lag and should not be read as a plateau. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Multi-year growth continues across healthcare informatics and sensor-diagnostics branches
Annual filing volume and the IPC branch breakdown together reveal both the pace of investment and where technical effort is concentrated. The trend chart covers 2017–2026, while the composition chart maps activity across nine IPC classes.
Annual filing trend
Filings were sparse before 2020, then accelerated sharply through 2023 — the peak year on record. Volume in 2024 and 2025 appears lower, but this reflects normal publication lag rather than a genuine contraction; the most recent years should be interpreted cautiously. The three-year recent window sits 95% above the prior three-year window, confirming net expansion on a multi-year basis.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Healthcare informatics (G16H) and diagnosis-and-surgery (A61B) dominate the branch mix, reflecting the dual focus on decision-support software and sensor-level measurement. Devices for body fluids (A61M) ranks third, capturing insulin-delivery integration. Branches such as AI-model computing (G06N), digital data processing (G06F), and signalling systems (G08B) are present but carry materially lower counts, pointing to relative sparsity in pure machine-learning and alert-logic filings.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
System, method and computer readable medium for co…
A system or method for compressing continuous glucose monitor (CGM) data for a subject and/or a technician, clinician, or for use with an interventional device. The system or method configures the CGM data to allow the subject, technician, clinician, or interventional device to take a physical action in response to receiving a transmission to improve the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | CGM-based prevention of hypoglycemia via hypoglyce… | 152 |
| 2 | CGM-based prevention of hypoglycemia via hypoglyce… | 138 |
| 3 | CGM-Based Prevention of Hypoglycemia Via Hypoglyce… | 82 |
| 4 | CGM-based prevention of hypoglycemia via hypoglyce… | 46 |
| 5 | Use of electrochemical impedance spectroscopy (EIS… | 44 |
| 6 | Methods for continuous glucose monitoring | 40 |
| 7 | 通过低血糖风险评估和平滑降低胰岛素递送的基于CGM的低血糖预防 | 37 |
| 8 | CGM-Based Prevention of Hypoglycemia Via Hypoglyce… | 28 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D prioritization
Four structural readings — maturity, concentration, collaboration, and geography — each carry distinct implications for teams deciding where to allocate resources.
Growth stage with annual volume easing from 2023 peak
The field is classified as Growth: the recent three-year filing window sits 95% above the prior three-year window, confirming multi-year expansion. Annual volume peaked in 2023 and has eased since, though publication lag accounts for much of the apparent recent softness. New entrants continue to appear, indicating that the window for staking foundational positions is not yet closed.
Growth stageTop five hold 88% of the hundred largest filers’ combined total
Concentration at this level — with a single academic institution (University of Virginia Patent Foundation, 78 patent records) holding roughly twice the count of the next-ranked commercial filer — is characteristic of a field where core algorithmic IP originated in a single research program. Entrants must either license foundational methods, design around them, or identify branches where the leaders have limited coverage.
High concentrationSparse co-filing; University of Virginia and Marc D. Breton are the active co-filer pair
Only two co-applicant relationships appear in the evidence: Marc D. Breton co-filing with the University of Virginia Patent Foundation on 2 patent records, and Dexcom co-filing with the University of Padova on 1 patent record. The near-absence of broad consortium activity suggests the field has not yet developed a multi-party standards-driven dynamic, leaving ecosystem collaboration as a potential strategic lever for challengers.
Limited co-filingUS-centric filing with selective EPO and PCT coverage
The United States accounts for 69 patent records at the jurisdiction level, with Europe (EPO) at 28 and WIPO (PCT) at 9 representing the main international routes. Canada, Australia, and China have limited coverage. The narrow geographic spread means protection outside North America and Europe is largely absent, which may matter as CGM adoption accelerates in Asian markets.
US-centricGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| BRETON MARC D | University of Virginia Patent Foundation | 2 |
| Dexcom Inc | University of Padova | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
University of Virginia anchors academic IP; Medtronic MiniMed and Dexcom lead commercial translation
The leader-challenger gap in this field is unusually wide, with the top academic filer holding more than twice the patent records of the nearest commercial rival. Recent momentum data show that commercial players are accelerating into the space as new entrants.
University of Virginia Patent Foundation
Holds 78 patent records, the largest position in the corpus by a substantial margin. Technology emphasis spans healthcare informatics decision-support (G16H 50, G16H 40) and sensor-level diagnosis (A61B 5), reflecting a vertically integrated research program covering both the modeling layer and clinical interface. Recent momentum shows a +54% increase, indicating the program continues to expand rather than consolidate.
78 patent recordsMedtronic MiniMed Inc
Holds 33 patent records and is classified as a new entrant in the recent filing window, with 7 patent records in the most recent period. Technology focus is concentrated on sensor diagnostics (A61B 5), insulin-delivery devices (A61M 5), and electrochemical material analysis (G01N 27), indicating a device-hardware and delivery-system orientation that complements rather than replicates the University of Virginia’s algorithmic coverage.
33 patent records| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| University of Virginia Patent Foundation | 20 | ▲ +54% |
| Medtronic MiniMed Inc | 7 | ▲ new entrant |
| WellDoc Inc | 8 | ▲ new entrant |
| Dexcom Inc | 3 | ▲ new entrant |
| University of Padova | 1 | ▲ new entrant |
| Universitat Politecnica de Valencia | 1 | ▲ new entrant |
| Zhongshan Hospital Fudan University | 1 | ▲ new entrant |
AI-model computing and digital signal alerting are under-served relative to technical relevance
Several IPC branches adjacent to the dominant healthcare-informatics core carry low filing counts despite plausible technical value in the context of real-time glucose dynamics. These are observations of relative sparsity; whether they represent viable entry points depends on regulatory path and integration complexity.
G06N · Computing based on AI models
Only 3 patent records land in the AI-model computing branch, representing roughly 1% of the branch-level activity in this corpus. Given that glucose prediction and closed-loop insulin dosing are natural domains for neural networks and reinforcement learning, the sparsity is notable. A realistic entry path exists for teams with ML-for-physiological-time-series capability, particularly if they target predictive models that sit outside the University of Virginia’s existing G16H-focused coverage.
Search this in Eureka →G08B · Signalling & alarm systems
The signalling and alarm systems branch holds only 2 patent records, roughly 1% of branch-level activity, despite CGM systems being clinically dependent on accurate hypoglycemia and hyperglycemia alerts. The most-cited patents in this corpus cluster around hypoglycemia prevention logic, yet the dedicated alarm-system branch remains sparse. Teams focused on alert-fatigue reduction, multi-modal notification, or interoperability with wearable alert platforms may find limited prior art in this sub-domain.
Search this in Eureka →How leaders differ by IPC technology route
Route coverage across the main technology branches in the current evidence set.
| Player | G16H 50 · Healthcare informatics | A61B 5 · Diagnosis & surgery | A61M 5 · Devices for body fluids | G16H 20 · Healthcare informatics | G16H 40 · Healthcare informatics |
|---|---|---|---|---|---|
| University of Virginia Patent Foundation | Strong · 78 | Strong · 54 | Moderate · 34 | Strong · 51 | Strong · 53 |
| Medtronic MiniMed Inc | Absent | Strong · 33 | Strong · 22 | Absent | Absent |
| Dexcom Inc | Strong · 8 | Absent | Strong · 6 | Strong · 8 | Strong · 7 |
| WellDoc Inc | Strong · 9 | Strong · 5 | Absent | Absent | Absent |
| BRETON MARC D | Strong · 2 | Moderate · 1 | Absent | Moderate · 1 | Strong · 2 |
| Abbott Diabetes Care Inc | Strong · 2 | Strong · 2 | Absent | Absent | Absent |
| DR HARISHCHANDER ANANDARAM | Strong · 1 | Strong · 1 | Absent | Absent | Absent |
Frequently asked questions
The corpus contains 74 patent families in scope across the CGM glucose dynamics modeling topic.
The University of Virginia Patent Foundation leads with 78 patent records, more than twice the count of the next-ranked filer, Medtronic MiniMed Inc at 33 patent records.
The field is in a Growth stage. The recent three-year filing window is 95% above the prior three-year window, confirming multi-year expansion. Annual volume peaked in 2023 and has eased since; the most recent years are further understated by publication lag and should not be interpreted as a genuine decline.
The United States accounts for the largest share at the jurisdiction level with 69 patent records, followed by Europe (EPO) at 28 and WIPO (PCT) at 9. Canada (7) and Australia (6) have moderate coverage; China, Germany, and India have limited filings.
Healthcare informatics (G16H) and diagnosis-and-surgery (A61B) are the two dominant IPC branches. Devices for body fluids (A61M) ranks third, reflecting insulin-delivery integration. AI-model computing (G06N) and signalling systems (G08B) are present but carry very low counts.
Co-filing activity is sparse. The two documented co-applicant relationships are: Marc D. Breton co-filing with the University of Virginia Patent Foundation on 2 patent records, and Dexcom Inc co-filing with the University of Padova on 1 patent record. No broad consortium activity is evident.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.